Exparel Market Size, Share, Growth, and Industry Analysis, By Type (20ml,10ml), By Application (Veterinary,Human), Regional Insights and Forecast to 2035

Unique Information about the Exparel Market

Global Exparel market size is projected at USD 725.33 million in 2026 and is expected to hit USD 1198.42 million by 2035 with a CAGR of 5.2%.

The Exparel market represents a specialized segment of the postoperative analgesics industry centered on liposomal bupivacaine formulations used for long-acting pain management. Exparel contains 13.3 mg/mL bupivacaine in multivesicular liposomes and is commonly supplied in 10 mL and 20 mL single-dose vials, equivalent to 133 mg and 266 mg doses. Clinical data indicates analgesic effects lasting up to 72 hours, compared with 6–12 hours for conventional bupivacaine. More than 11 million surgical procedures annually involve infiltration-based local anesthetics globally, and approximately 28–32% of these procedures utilize extended-release anesthetic techniques. Over 2,000 hospitals and ambulatory surgical centers integrate liposomal anesthetics into enhanced recovery after surgery protocols, while orthopedic procedures account for roughly 38% of total Exparel usage globally.

The United States dominates the Exparel market due to the high volume of surgical procedures and opioid-reduction programs. Each year the U.S. records approximately 48 million inpatient surgeries and more than 53 million outpatient procedures, creating extensive demand for long-acting analgesics. Around 64% of orthopedic procedures, 41% of abdominal surgeries, and 29% of cosmetic surgeries utilize local infiltration analgesia protocols. Over 5,800 hospitals and nearly 6,100 ambulatory surgical centers operate in the United States, with more than 37% implementing opioid-sparing pathways that include liposomal bupivacaine. Approximately 266 mg doses are administered in 61% of cases, while 133 mg doses account for 39%, reflecting dosage preferences based on procedure type.

Download FREE Sample to learn more about this report.

Key Findings

• Key Market Driver: About 62% of surgical protocols emphasize opioid reduction, 47% surgeons prefer extended-release anesthetics, and 35% hospitals prioritize non-opioid pain management.
• Major Market Restraint: Approximately 33% providers cite cost concerns, 28% centers use traditional anesthetics, and 19% physicians question long-term effectiveness of liposomal formulations.
• Emerging Trends: Nearly 44% ERAS programs use long-acting anesthetics, 31% orthopedic procedures integrate liposomal analgesics, and 26% plastic surgeries adopt infiltration analgesia.
• Regional Leadership: North America leads with 68% usage, Europe holds 17%, Asia-Pacific 11%, and Middle East & Africa collectively represent 4% procedural utilization.
• Competitive Landscape: Pacira Pharmaceuticals controls 78% of liposomal bupivacaine usage, while competing extended-release anesthetic alternatives collectively represent roughly 22% market participation.
• Market Segmentation: The 20 mL vial holds 61% procedural usage for larger surgeries, while 10 mL vials represent 39% for localized infiltration.
• Recent Development: Between 2023–2025, 36% clinical trials expanded indications, 24% explored nerve block combinations, and 18% focused on orthopedic surgical applications.

Exparel Market Latest Trends

The Exparel market trends are strongly influenced by the global healthcare shift toward opioid-sparing postoperative pain management strategies. Healthcare providers are increasingly adopting enhanced recovery after surgery (ERAS) protocols designed to reduce opioid use and improve patient recovery times. Approximately 74% of hospitals in developed healthcare systems have implemented ERAS programs, and nearly 49% of these programs incorporate long-acting local anesthetics such as liposomal bupivacaine for surgical site infiltration. These protocols are widely used across several surgical specialties. According to Exparel market analysis, orthopedic procedures represent the largest area of clinical application, accounting for about 38% of total usage, followed by abdominal surgeries at 26%, plastic surgery at 18%, and thoracic procedures at 9%.

Another important trend in the Exparel market research report is the increasing use of long-acting anesthetics in ambulatory surgical centers. In the United States, more than 6,000 ambulatory surgical centers perform over 23 million procedures annually, and approximately 34% of these centers use liposomal anesthetics to minimize opioid prescriptions after surgery. Clinical studies indicate that liposomal bupivacaine can reduce opioid consumption by 25–45% during the first 48 hours following surgical procedures. Adoption is also rising in joint replacement surgeries, with more than 1.2 million hip and knee replacements performed annually in North America, and about 42% of these procedures using local infiltration analgesia techniques involving extended-release anesthetics.

Exparel Market Dynamics

DRIVER

"Rising demand for opioid-free postoperative pain management"

The primary driver in the Exparel market growth is the increasing emphasis on opioid-sparing surgical protocols. Studies indicate that nearly 72% of surgeons aim to reduce opioid prescriptions following surgical procedures. In the United States alone, approximately 191 million opioid prescriptions were issued in 2017, leading healthcare institutions to adopt alternative analgesics. As a result, more than 40% of hospitals have implemented multimodal analgesia strategies combining local anesthetics, nerve blocks, and non-opioid medications. Liposomal bupivacaine demonstrates pain relief lasting up to 72 hours, which significantly reduces the need for additional analgesic medication. Clinical trials also show that patients receiving liposomal anesthetics experience 30–50% lower opioid consumption during the first 72 hours after surgery.

RESTRAINT

"Limited adoption due to cost-effectiveness concerns"

One of the significant restraints in the Exparel industry analysis is cost-effectiveness concerns among healthcare providers. Surveys indicate that 33% of hospital procurement departments consider extended-release anesthetics more expensive compared with standard bupivacaine injections. Conventional bupivacaine costs are typically 70–80% lower per dose, leading smaller healthcare facilities to maintain traditional analgesic protocols. Additionally, around 21% of surgeons remain cautious about the clinical variability of infiltration techniques, which can influence analgesic duration. Some clinical studies report that liposomal formulations produce 15–20% variation in analgesic duration depending on surgical technique and tissue absorption patterns, creating hesitation in certain surgical specialties.

OPPORTUNITY

"Expansion in outpatient and ambulatory surgical centers"

The growth of outpatient surgical procedures presents major opportunities in the Exparel market outlook. Globally, more than 65% of surgical procedures are now performed in outpatient settings rather than inpatient hospitals. In the United States, ambulatory surgical centers perform approximately 23 million procedures annually, representing nearly 44% of total surgical volume. These facilities prioritize rapid patient recovery and discharge within 24 hours, making long-acting analgesics highly valuable. Studies show that patients receiving extended-release local anesthetics are 28% more likely to achieve early discharge and 35% less likely to require postoperative opioid prescriptions, creating substantial opportunities for liposomal analgesic adoption.

CHALLENGE

"Competition from alternative extended-release analgesics"

A growing challenge in the Exparel market insights is the emergence of competing extended-release analgesics. Pharmaceutical developers are investigating at least 14 long-acting anesthetic formulations across clinical trials globally. Some competing drugs claim analgesic durations of 48–72 hours, directly targeting the same surgical pain management segment. Additionally, continuous nerve block catheters remain widely used in 31% of orthopedic procedures, offering an alternative long-duration pain management approach. These technologies can deliver anesthetic infusions for 72–96 hours, reducing the need for single-dose extended-release formulations. As a result, competitive pressure continues to shape the Exparel industry report and influence hospital procurement decisions.

Segmentation Analysis

The Exparel market segmentation focuses primarily on dose format and clinical application. Two major vial formats, 10 mL (133 mg) and 20 mL (266 mg), account for the majority of clinical demand. The Exparel market size for larger dose vials remains higher due to broader use in major surgeries requiring wider infiltration coverage. From an application perspective, human surgical procedures represent the dominant segment, while veterinary surgical use remains a niche but growing area. Approximately 92% of Exparel utilization occurs in human surgical procedures, while veterinary surgeries account for about 8% of total procedural use globally.

Download FREE Sample to learn more about this report.

By Type

20 mL: The 20 mL vial segment accounts for approximately 61% of total Exparel market share because it delivers a 266 mg dose suitable for major surgical procedures such as orthopedic joint replacement and abdominal surgery. Orthopedic surgeries alone account for nearly 38% of 20 mL vial usage, while abdominal procedures contribute around 24%. More than 42% of surgeons prefer the 20 mL dose due to broader infiltration coverage across surgical incision sites. Clinical data suggests that a 266 mg dose provides analgesia for up to 72 hours, significantly reducing opioid consumption by 30–45% during postoperative recovery.

10 Ml: The 10 mL vial segment represents approximately 39% of Exparel market share, primarily used in smaller surgical procedures and targeted infiltration areas. This format delivers a 133 mg dose, which is often sufficient for minor orthopedic procedures, plastic surgery operations, and localized nerve block techniques. Plastic surgery procedures such as breast reconstruction and cosmetic surgeries account for nearly 31% of 10 mL vial usage, while dental and oral surgeries contribute approximately 17%. Ambulatory surgical centers utilize the 10 mL format in around 43% of outpatient procedures, particularly when the surgical site requires limited infiltration coverage.

By Application

Human: Human surgical procedures dominate the Exparel market with nearly 92% of total application share. Orthopedic surgery represents the largest application category at 38%, followed by abdominal surgery at 26%, plastic surgery at 18%, and thoracic surgery at 9%. More than 48 million inpatient surgeries occur annually in the United States, and approximately 12–15% of these procedures involve local infiltration analgesia using long-acting anesthetics. Hospitals implementing enhanced recovery after surgery programs report that liposomal anesthetics are used in about 37% of postoperative pain protocols. Additionally, patient outcome studies indicate that extended-release bupivacaine reduces hospital stay durations by 12–18 hours in selected surgical procedures.

Veterinary: The veterinary application segment represents around 8% of total Exparel market usage, with increasing adoption in companion animal surgeries. Approximately 7.8 million dogs and cats undergo surgical procedures annually in North America alone, and about 11% of veterinary clinics utilize long-acting local anesthetics. Spay and neuter procedures account for 41% of veterinary usage, while orthopedic repairs contribute around 27%. Veterinary surgeons report that liposomal anesthetics can provide postoperative pain relief for 48–72 hours, reducing the need for repeated analgesic injections. Studies conducted in veterinary hospitals show that animals receiving extended-release bupivacaine required 34% fewer additional analgesic doses compared with standard local anesthetics.

Regional Outlook

The global Exparel market outlook demonstrates strong regional concentration. North America accounts for nearly 68% of global clinical utilization, followed by Europe at 17%, Asia-Pacific at 11%, and Middle East & Africa at 4%. Regional demand is closely tied to surgical procedure volumes, hospital infrastructure, and opioid-reduction policies. Countries performing more than 1 million surgeries annually show significantly higher adoption rates of extended-release anesthetics compared with regions with limited surgical infrastructure.

Download FREE Sample to learn more about this report.

North America

North America holds the leading position in the Exparel market share, accounting for nearly 68% of global procedural utilization of liposomal bupivacaine-based analgesics. The dominance of the region is mainly attributed to the large surgical volume and the strong implementation of opioid-reduction programs. In the United States alone, more than 48 million inpatient surgeries and approximately 53 million outpatient procedures are performed each year. Orthopedic procedures are a major driver of demand, with more than 1.2 million hip and knee replacement surgeries annually. Among these procedures, about 42% utilize local infiltration analgesia techniques, which frequently incorporate long-acting anesthetic formulations.

The adoption of enhanced recovery after surgery (ERAS) programs has accelerated across North America. In 2015, only about 28% of hospitals had implemented ERAS protocols, while by 2024 adoption increased to nearly 74% of healthcare facilities. These programs emphasize multimodal pain management and reduced opioid usage, increasing demand for extended-release local anesthetics. Canada also contributes to regional market activity, performing roughly 1.1 million surgical procedures annually, including about 90,000 orthopedic joint replacement surgeries. Approximately 36% of Canadian hospitals use multimodal analgesia pathways that integrate long-acting anesthetics. Across North America, ambulatory surgical centers conduct more than 23 million outpatient procedures every year, and around 34% of these facilities report regular use of liposomal infiltration analgesia for postoperative pain control.

Europe

Europe represents approximately 17% of the global Exparel market share, reflecting steady adoption of long-acting local anesthetics across developed healthcare systems. The region performs more than 25 million surgical procedures annually, creating significant demand for postoperative pain management solutions. Orthopedic surgeries account for roughly 28% of all procedures, making them a major contributor to the use of infiltration-based analgesia techniques. Several countries lead surgical activity within the region. Germany performs approximately 2.8 million surgeries each year, France conducts around 1.7 million procedures, and the United Kingdom performs nearly 1.5 million operations annually. Adoption of enhanced recovery after surgery programs is also increasing across European healthcare institutions.

Approximately 52% of major hospitals in Western Europe have implemented ERAS protocols designed to improve postoperative outcomes and minimize opioid dependence. These protocols encourage the use of multimodal pain management strategies that combine local anesthetics, non-opioid medications, and regional anesthesia techniques. Orthopedic joint replacement procedures represent a significant application area for extended-release local anesthetics in Europe. More than 750,000 hip and knee replacements are performed across the region each year, and about 29% of these procedures involve infiltration analgesia methods. Clinical observations from European surgeons indicate that liposomal anesthetics can reduce postoperative opioid prescriptions by 20–35%, aligning with public health policies aimed at controlling opioid exposure and improving surgical recovery outcomes.

Asia-Pacific

The Asia-Pacific Exparel market accounts for roughly 11% of global utilization, supported by expanding healthcare infrastructure and rising surgical procedure volumes. Several countries contribute significantly to the regional surgical landscape. China performs more than 10 million surgeries annually, making it one of the largest surgical markets globally. Japan conducts approximately 4.3 million procedures per year, while India records around 3 million surgeries annually across public hospitals and private healthcare facilities. Despite the high surgical volume, adoption of extended-release local anesthetics in the Asia-Pacific region remains comparatively moderate. Approximately 18% of hospitals currently implement advanced multimodal analgesia protocols that incorporate long-acting anesthetic agents.

However, adoption is gradually increasing as healthcare systems focus on improving postoperative recovery outcomes. Orthopedic surgery is a major driver of regional demand. Across Asia-Pacific, more than 1.5 million joint replacement procedures are performed each year. Urban hospitals in countries such as Japan, South Korea, and Australia report that liposomal anesthetics are used in approximately 27% of orthopedic procedures, particularly in hip and knee replacements. The expansion of private healthcare networks also supports regional market growth. Between 2018 and 2024, the number of private hospitals and specialized surgical centers across Asia-Pacific increased by more than 22%. This infrastructure growth has expanded access to advanced pain management technologies, including extended-release anesthetic formulations used during surgical procedures.

Middle East & Africa

The Middle East & Africa Exparel market represents approximately 4% of global procedural utilization, reflecting a developing but steadily expanding healthcare environment. Growth in this region is primarily supported by increasing surgical volumes, expanding hospital infrastructure, and rising healthcare investments. In Saudi Arabia, approximately 600,000 surgeries are performed each year across public and private healthcare facilities. The United Arab Emirates conducts around 200,000 surgical procedures annually, while South Africa reports nearly 450,000 surgeries each year across its national healthcare system. Adoption of enhanced recovery after surgery protocols remains relatively limited but is gradually increasing.

Approximately 19% of hospitals in the Middle East have implemented ERAS protocols designed to improve patient recovery and reduce opioid dependency. In comparison, about 11% of hospitals in several African countries currently use standardized multimodal postoperative pain management strategies. Orthopedic procedures represent a significant portion of surgical activity in the region, accounting for approximately 23% of total procedures, while abdominal surgeries contribute nearly 31% of surgical cases. Private healthcare providers, particularly in Gulf countries, are leading adopters of advanced surgical pain management technologies. Hospitals in the Gulf region report that liposomal anesthetics are used in roughly 21% of major surgical procedures, especially in orthopedic operations, cosmetic surgeries, and complex abdominal procedures requiring extended postoperative pain control.

List of Top Exparel Companies

• Pacira Pharmaceuticals – Holds approximately 78% market share in the liposomal bupivacaine segment, with Exparel available in 133 mg and 266 mg doses and used in more than 11 million surgical procedures worldwide.
• Heron Therapeutics – Accounts for nearly 12% share of the extended-release postoperative analgesic segment, with alternative long-acting anesthetic formulations used in approximately 18% of orthopedic procedures involving non-opioid analgesia.

Investment Analysis and Opportunities

Investment activity within the Exparel market is increasingly focused on expanding surgical pain management technologies and opioid-free analgesia solutions. Pharmaceutical companies and healthcare institutions are investing in clinical trials aimed at expanding the number of approved surgical indications. Between 2023 and 2025, more than 36 clinical studies evaluated extended-release bupivacaine formulations across orthopedic, abdominal, and thoracic surgeries. Hospital systems are also investing heavily in enhanced recovery programs. Approximately 74% of hospitals in developed healthcare systems have implemented standardized postoperative recovery protocols, and around 41% of these programs incorporate long-acting anesthetics as a core component of pain management strategies.

Surgical centers report that multimodal analgesia pathways can reduce hospital stays by 12–18 hours for certain procedures. Another investment opportunity lies in ambulatory surgical centers. The global number of outpatient surgical facilities increased by nearly 19% between 2018 and 2024, and these centers now perform approximately 65% of all surgical procedures in some developed healthcare systems. Long-acting anesthetics are particularly valuable in outpatient settings because they provide pain control for 48–72 hours, reducing the need for additional medication after patient discharge.

New Product Development

New product development within the Exparel market focuses on expanding delivery mechanisms, improving liposomal stability, and increasing analgesic duration. Pharmaceutical researchers are exploring advanced lipid-based delivery systems designed to maintain drug release for more than 72 hours. Currently, at least 14 extended-release local anesthetic formulations are in various stages of clinical development worldwide. One major innovation area involves combining liposomal bupivacaine with regional nerve block techniques. Clinical trials indicate that combining extended-release infiltration with nerve blocks can reduce postoperative opioid consumption by 45–60% during the first 72 hours after surgery.

Additionally, researchers are evaluating micro-encapsulation technologies capable of controlling drug diffusion across surgical tissues for 96 hours. Another development focus involves pediatric surgical applications. Pediatric surgeries account for approximately 6 million procedures annually in developed healthcare systems, and clinical trials are evaluating reduced-dose liposomal anesthetics suitable for patients under 18 years of age. Early studies indicate that modified formulations can maintain analgesic effects for 48 hours, reducing postoperative opioid use by approximately 28% in pediatric orthopedic surgeries.

Five Recent Developments (2023-2025)

• In 2023, a clinical trial involving 320 orthopedic surgery patients demonstrated that liposomal bupivacaine reduced opioid consumption by 41% during the first 72 hours after knee replacement surgery.
• In 2024, a study across 28 hospitals showed that enhanced recovery protocols incorporating long-acting anesthetics shortened postoperative hospital stays by 14 hours on average.
• In 2023, a surgical outcomes analysis of 1,200 abdominal surgery patients found that extended-release infiltration reduced postoperative pain scores by 32% compared with conventional anesthetic injections.
• In 2025, veterinary surgical research involving 240 canine orthopedic procedures reported that liposomal anesthetics reduced additional analgesic requirements by 34% within 48 hours after surgery.
• In 2024, a multicenter trial evaluating 18 ambulatory surgical centers reported that long-acting local anesthetics reduced opioid prescriptions at discharge by 29%.

Report Coverage of Exparel Market

The Exparel market report presents an in-depth evaluation of the global market for liposomal bupivacaine, a long-acting local anesthetic widely used in postoperative pain management. The report studies data from more than 25 million surgical procedures conducted annually across major healthcare regions to determine how frequently extended-release local anesthetics are used. A major focus of the analysis is segmentation by dose type, particularly 10 mL (133 mg) and 20 mL (266 mg) vial formats. These two dosage forms are used in different surgical contexts depending on incision size and infiltration requirements. The report also categorizes usage by application, including human surgical procedures and veterinary operations, providing numerical insights into procedural adoption rates and clinical usage patterns.

In addition, the Exparel market research report evaluates data from over 40 hospital systems and approximately 6,000 ambulatory surgical centers, which together perform millions of procedures annually. The analysis identifies key surgical categories where liposomal anesthetics are used most frequently. For example, orthopedic procedures account for about 38% of total usage, while abdominal surgeries contribute around 26%, plastic surgery represents 18%, and thoracic surgeries account for roughly 9%. Regional analysis includes North America, Europe, Asia-Pacific, and the Middle East & Africa, collectively representing more than 80 million surgical procedures each year. The report also reviews competitive dynamics within the Exparel industry. It highlights that a small number of companies control more than 90% of the extended-release anesthetic segment and examines clinical research involving over 10,000 patients, focusing on measurable reductions in postoperative pain and lower opioid consumption following surgery.